Belinostat-d5
Belinostat-d5 (PXD101-d5) is the deuterium labeled Belinostat (HY-10225). Belinostat (PXD101; PX105684) is a potent HDAC inhibitor with an IC50 of 27 nM in HeLa cell extracts.
For research use only. We do not sell to patients.
- CAS No.: 2130852-65-0
- Formula: C15H9D5N2O4S
- Molecular Weight:323.38
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 2130852-65-0
-
Unlabeled Cas 866323-14-0
-
Molecular Weight 323.38
-
Formula C15H9D5N2O4S
-
SMILES
O=S(NC1=C([2H])C([2H])=C([2H])C([2H])=C1[2H])(C2=CC(/C=C/C(NO)=O)=CC=C2)=O
-
Synonyms
PXD101-d5; PX105684-d5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Plumb JA, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histonedeacetylase inhibitor PXD101. Mol Cancer Ther. 2003 Aug;2(8):721-8. [Content Brief]
[2]. Qian X, et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther. 2006 Aug;5(8):2086-95. [Content Brief]
[3]. Chia S, et al. Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nat Commun. 2017 Sep 5;8(1):435. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)